{"id":"NCT03818607","sponsor":"Amgen","briefTitle":"A Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Participants With PNH","officialTitle":"A Randomized, Double-Blind, Active-Controlled Phase 3 Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-01-22","primaryCompletion":"2022-07-12","completion":"2022-07-12","firstPosted":"2019-01-28","resultsPosted":"2023-05-23","lastUpdate":"2023-05-23"},"enrollment":42,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Paroxysmal Nocturnal Hemoglobinuria"],"interventions":[{"type":"DRUG","name":"ABP 959","otherNames":["Treatment T"]},{"type":"DRUG","name":"Eculizumab","otherNames":["Soliris","Treatment R"]}],"arms":[{"label":"T (ABP 959) / R (eculizumab)","type":"OTHER"},{"label":"R (eculizumab) / T (ABP 959)","type":"OTHER"}],"summary":"This is a randomized, double-blind, active-controlled phase 3 study of ABP 959 in participants with paroxysmal nocturnal hemoglobinuria.","primaryOutcome":{"measure":"LDH Level at Week 27 (Parallel Comparison)","timeFrame":"Week 27","effectByArm":[{"arm":"ABP 959","deltaMin":205.69,"sd":null},{"arm":"Eculizumab","deltaMin":193.53,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":12},"locations":{"siteCount":24,"countries":["United States","Czechia","Finland","France","Ireland","Italy","Netherlands","Norway","Portugal","Slovenia","Spain","Sweden","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["39171864"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":20},"commonTop":["Headache","Anaemia","Nasopharyngitis","Pyrexia","Vaccination complication"]}}